CTOs on the Move


 
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aeglea.com
  • 221 Crescent Street, Building 17 Suite 102B
    Waltham, MA USA 02453
  • Phone: 512.942.2935

Executives

Name Title Contact Details

Similar Companies

Capital Royalty L.P.

Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Threshold Enterprises

Threshold Enterprises is a wholesale distributor of dietary supplements and health care products to the natural foods industry and health care professionals. We don't sell directly to consumers. If you want to open an account, or are a current customer

Avanir

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide.

Refuge Biotechnologies

Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient`s body.

Oxyband Technologies

Oxyband Technologies, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.